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Abstract
Introduction: Ventilator-associated pneumonia (VAP) increases mortality in critical illness. However, clinical diagnostic
uncertainty persists. We hypothesised that measuring cell-surface and soluble inflammatory markers, incorporating
Triggering Receptor Expressed by Myeloid cells (TREM)-1, would improve diagnostic accuracy.
Methods: A single centre prospective observational study, set in a University Hospital medical-surgical intensive Care unit,
recruited 91 patients into 3 groups: 27 patients with VAP, 33 ventilated controls without evidence of pulmonary sepsis (non-
VAP), and 31 non-ventilated controls (NVC), without clinical infection, attending for bronchoscopy. Paired samples of
Bronchiolo-alveolar lavage fluid (BALF) and blood from each subject were analysed for putative biomarkers of infection:
Cellular (TREM-1, CD11b and CD62L) and soluble (IL-1b, IL-6, IL-8, sTREM-1, Procalcitonin). Expression of cellular markers on
monocytes and neutrophils were measured by flow cytometry. Soluble inflammatory markers were determined by ELISA. A
biomarker panel (‘Bioscore’), was constructed, tested and validated, using Fisher’s discriminant function analysis, to assess
its value in distinguishing VAP from non VAP.
Results: The expression of TREM-1 on monocytes (mTREM-1) and neutrophils (nTREM-1) and concentrations of IL-1b, IL-8,
and sTREM-1 in BALF were significantly higher in VAP compared with non-VAP and NVC (p,0.001). The BALF/blood mTREM-
1 was significantly higher in VAP patients compared to non-VAP and NVC (0.8 v 0.4 v 0.3 p,0.001). A seven marker Bioscore
(BALF/blood ratio mTREM-1 and mCD11b, BALF sTREM-1, IL-8 and IL-1b, and serum CRP and IL-6) correctly identified 88.9%
of VAP cases and 100% of non-VAP cases.
Conclusion: A 7-marker bioscore, incorporating cellular and soluble TREM-1, accurately discriminates VAP from non-
pulmonary infection.
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Introduction
Ventilator-associated pneumonia (VAP) remains a common
complication of critical illness, affecting over 10% of intubated
patients, prolonging ICU stay, with an estimated attributable
mortality of 13% [1–3]. This is despite the introduction of health
improvement strategies such as Ventilator care bundles, which
have apparently reduced the incidence [4,5], even though
antibiotic prescriptions remain high for pulmonary sepsis in ICU
[5]. Standardisation of diagnostic criteria for VAP is important for
benchmarking, but no single best definition exists [6]. This in part
has led to proposals for simplifying definitions into infective and
non-infective ventilator associated complications [7].
Confirmatory diagnosis by microbiological culture is often too
slow for clinical need, whilst even quantitative microbiological
analysis is subject to the variations in the sampling site, or elusive
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despite other criteria being fulfilled [8]. Biomarkers may facilitate
clinical confirmation and aid differentiation of pulmonary from
non-pulmonary sepsis. This would allow earlier, targeted antibiotic
intervention, direct clinicians’ decision-making for ‘antibiotic de-
escalation’ regimens and potentially reduce selective pressure for
multi-resistant bacteria [9,10]. The role of inflammatory biomark-
ers including TREM-1 (Triggering Receptor Expressed on
Myeloid Cells-1), IL-1, IL-6, IL-8, Procalcitonin (PCT) and more
traditional indices, i.e. white cell count and CRP remains unclear.
Only some show clinical diagnostic utility for VAP [11–14].
Differences in definitions of VAP patient populations, severity of
disease, and assay techniques account for much of the conflicting
data reported [15,16]. Furthermore, failure of many studies to
consider the dynamic relationships between soluble and cell
surface inflammatory proteins (e.g.TREM-1), differential expres-
sion of inflammatory markers by neutrophils and monocytes, and
compartmentalization of inflammatory immune responses at the
site of tissue infection in reference to blood, are likely contributory
factors.
The aim of this study was to determine if, and which
combination of paired blood and bronchoalveolar lavage fluid
(BALF) inflammatory biomarkers (soluble and cell surface based,
including TREM-1), could correctly classify patients with VAP
from ventilated patients without evidence of pulmonary sepsis.
Materials and Methods
Study participants
Informed, witnessed and written assent was obtained from a
relative or designated carer for all ventilated patients. Written
consent was obtained from all day case bronchoscopy patients.
Ethical permission was obtained from the local institutional board
(Barking and Havering Local Research Ethics Committee, Ilford,
Essex, UK), through the National Research Ethics Service (NRES)
of the United Kingdom 08/H0702/61.
The study sample was selected from patients hospitalized
between Feb 2009 and Aug 2011 in the Intensive Care unit, and
Lady Kilmarnock bronchoscopy suite of the Chelsea and
Westminster Hospital NHS Foundation Trust, London, United
Kingdom. Adult patients (.18 years) were recruited into the
following 3 groups; ventilator associated pneumonia, ventilated
controls without evidence of pulmonary sepsis or with non-
pulmonary sepsis (non-VAP), and non-ventilated non-infected
controls (NVC).
In accordance with the 2005 guidelines of the American
Thoracic Society/Infectious Diseases Society of America, the
criteria for diagnosis of VAP were evidence of new infiltrates on
chest radiographs after 48 hours of endotracheal intubation and
presence of at least 2 of the following: fever (temperature .38uC
or higher than basal temperature), abnormal white cell count ($10
000/mL or ,4000/mL), and purulent respiratory tract secretions
[2]. As per recommendations, BALF samples were collected via
directed bronchoscopy, semi-quantitatively reported (SQ) and
cultured for microorganisms [17].
The clinical pulmonary infection score (CPIS) defined VAP and
non-VAP [17,18]. Thus, VAP was predefined as CPIS .5 and
positive BALF microbiology. Non-VAP was predefined as CPIS
score ,6 and negative microbiology. This was a modification of
the original CPIS, by additionally incorporating SQ microbiolog-
ical data. The patient cohorts comprised non-infected ventilated
patients, or individuals with non-pulmonary infection (i.e. intra-
abdominal, indwelling devices) confirmed on clinical, radiological
and microbiological grounds. To control for the effects of
mechanical ventilation on pulmonary inflammation, BALF and
blood samples were obtained from a cohort of non-ventilated
control patients (NVC) undergoing day case bronchoscopy for
non-infective respiratory disorders (i.e., chronic obstructive pul-
monary disease, COPD, interstitial lung disease, ILD, or solitary
pulmonary nodules).
Comparison of CPIS with the European Hospitals in Europe
Link for Infection Control through Surveillance programme
(HELICS) criteria (PN4) revealed excellent concordance using
the Cohen kappa statistic (0.95) [15,19]. Two patients with VAP
would have been classified as non-VAP using HELICS and one
patient with non-VAP could possibly have been placed into the
VAP cohort. Initial chest radiographic interpretation was that of
the clinical investigators, with all radiographs being independently
confirmed by a radiologist.
Data on exclusion criteria, and description of procedures for
obtaining informed consent and for sampling, processing of BALF
and blood and group classification are provided in an online
supplement.
Laboratory studies
Twenty two individual inflammatory markers were measured.
In blood these consisted of six cell surface [3 monocytic and 3
neutrophilic (TREM-1, CD11b and CD62L)] and five soluble
proteins sTREM-1, IL-6, PCT, CRP and the white cell count
(WCC). In BALF, the same six cell surface markers were measured
and five soluble proteins above the limit of detection for ELISA
were sTREM-1, IL-1b, IL-6, IL-8 and PCT. Nine BALF/blood
marker ratios were calculated.
Immunophenotypic analysis was performed on peripheral blood
and BALF cell suspensions using 5-colour flow cytometry
(Cytomics FC500 Beckman Coulter, Beckman-Coulter, Villepinte,
France). Blood and BALF cells were isolated following standard
centrifugation procedures, and washed in phosphate buffered
saline/1% fetal calf serum (FCS). 100 ml aliquot cell suspensions
were then stained with monoclonal antibodies for 30 minutes.
Further details on monoclonal antibodies used, on instrumentation
and software analysis are provided in an on line supplement.
CD45 staining and side scatter properties were initially used to
select CD14 and CD16 positive cells as markers of monocytes and
neutrophils respectively. Isotype controls were used to delineate
specific protein expression on the cell surface of inflammatory
cells. Geometric mean fluorescent intensity (MFI) was used as an
index of protein concentration expressed by a particular blood or
BALF cell population. Details on measurement of cytokines and
inflammatory mediators (sTREM-1, IL-1b, IL-6 and IL-8) and
PCT are provided in an online supplement. Urea was determined
by ELISA (Abcam, Cambridge, UK) and was used to correct for
dilutional effects in BALF [20].
Statistical Analysis
Anthropometric data was reported as medians and inter-
quartile ranges. Differences between the groups for individual
biomarkers were determined using the Kruskal-Wallis test
followed by the Mann-Whitney U test with Dunn’s post-hoc
correction for multiple analyses when there were any statistical
differences between individual groups.
Fisher’s discriminant function analysis (FDA) was used to
determine the optimal combination of biomarkers that could
discriminate between VAP and non-VAP patient groups. A
variable was entered into the ‘‘model’’ if the significance level of its
F-value was ,0.05 and was removed if the significance level was
$0.05. The model was then used to classify each of the 91 cases
into a diagnostic group. In order to check that the result of the
biomarker model was not skewed by the presence of outlier data
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the model was internally validated by means of the leave-one-out
method, which involves omitting a single observation from the
original sample, and then using the remaining observations to
assign the omitted case either to the VAP or non-VAP patient
group.
The model was cross-validated by repeat random sub-sampling
- by repeatedly (10 times) randomly assigning original cases into a
training cohort (60% of original cases) to obtain new classification
function coefficients for the analytes derived from the original
model. The new function coefficients obtained were applied to a
test cohort that consisted of the remaining cases (40%), to confirm
the reliability of the model [21–24]. Further statistical information
is available in an online supplement. All analysis was conducted
using the SPSS v19 software package (SPSS, Chicago, IL, USA)
and GraphPad Prism software (California, USA). Independent
statistical analysis was performed.
Results
Study participants
Ninety one patients were recruited consecutively. There were 27
VAP, 33 non-VAP and 31 NVC patients (Table 1). There were no
statistically significant differences between the groups with respect
to age, sex, history of cigarette smoking, presence of chest x-ray
infiltrates and APACHE II score. Twenty eight-day mortality was
3 deaths in the VAP group, 4 in the non-VAP group (none in the
NVC). The majority of patients in the VAP and non-VAP groups
were receiving antibiotics at the time of sampling. Thirty percent
of ventilated patients received steroids for sepsis. The distribution
of steroids between VAP and non-VAP groups were not
statistically significant. Nine VAP and 13 non-VAP patients were
post-operative cases. Within the NVC group, 7 patients had lung
cancer, 9 COPD, 2 pulmonary sarcoidosis, 1 lung fibrosis, 6 with
benign lung nodules and 7 with normal findings.
The following organisms were isolated (patients): Serratia
marcescens (2), Klebsiella spp (4), Pseudomonas spp (9), methicillin
sensitive staphylococcal aureus, MSSA (4), methicillin resistant
staphylococcal aureus, MRSA (3), Escherischia coli, (5), Acineto-
bacter baumanii (5), Stenotrophomonas (2) and Proteus mirabilis
(2). Twenty eight organisms were isolated from VAP patients and
the remaining eight bacteria were found in non-VAP patients
(non-pulmonary infection).
The CRP was significantly elevated in VAP and non-VAP
compared to NVC group (p,0.001). White cell count was
significantly higher in VAP than NVC (p,0.001). Neither CRP
nor WCC distinguished VAP from non-VAP.
Cellular and soluble inflammatory mediators in blood
In blood, there was no significant difference in the expression of
cellular and soluble biomarkers between VAP and non-VAP
(Table 2). However, the concentration of sTREM-1, IL-6, PCT
and expression of CD62L on CD14 gated monocytes were
significantly higher in VAP and non-VAP groups compared with
NVC (Table 2). This suggests blood based biomarker activation
resulting from ventilation, but that it is not discriminatory between
VAP and non-VAP patients.
Cellular and soluble inflammatory mediators in BALF
By contrast, analysis of BALF showed significantly increased
expression of cellular mTREM-1 and nTREM-1, and increased
concentration of soluble IL-1b in VAP compared with non-VAP
and NVC groups (p,0.001) (Table 2). Furthermore, whilst the
increased expression of mTREM-1 from BALF in VAP was
significant (p,0.001) (Figure 1a), this difference between VAP and
the other two groups was greater when the compartmentalization
ratio BALF/blood mTREM-1 was used (Figure 1b). This was not
the case for BALF/Blood nTREM-1. The BALF/Blood ratios of
CD11b on monocytes and sTREM-1 were also significantly higher
Table 1. Characteristics of patients recruited to study.
VAP Non-VAP NVC
Number of patients 27 33 31
Age 68 (23–84) 62 (18–89) 59 (18–84)
Sex (% male/% female) 70/30 52/48 61/39
CPIS 7 (6–9) 3 (0–5) N/A
Microbiology (% +ve) 100 12 0
APACHE II score 18 (5–45) 15 (2–24) N/A
Smoking (% current/ex/none) 44/15/40 30/21/49 35/13/52
Antibiotics (% pre-BALF) 89 70 32
CXR (% with shadowing) 96 55 81
Steroids (%) 30 30 6
28-day mortality (%) 11 12 0
Post-surgical (%) 37 39 0
Burns injury (% of cases) 15 15 0
WCC (x109/l) 15 (4–24) 9 (3–27) 7 (3–18)*
CRP (mg/L) 84 (7–320) 102(2–341){ 6 (1–296)*
The median and range (lowest-highest) is shown for each group. APACHE II and CPIS are only applicable to the ventilated patients. Some variables are presented as
percentages. Statistically significant differences between the groups were determined using the Mann-Whitney U test with post-hoc Dunn correction and are indicated
as follows: VAP versus NVC (p,0.001)* and non-VAP versus NVC (p,0.001){. CPIS =Clinical Pulmonary Infection Score. APACHE II = Acute Physiology and Chronic Health
Evaluation II score. VAP = ventilator-associated pneumonia. NVC= non-ventilated control. Non-VAP= ventilated non-pulmonary infected control. CXR = Chest X-ray.
WCC=White cell count. CRP= C-reactive protein.
doi:10.1371/journal.pone.0109686.t001
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in VAP group compared to non-VAP, but not when compared to
NVC (Table 2). The expression of cellular mTREM-1, nTREM-
1, and CD11b was lower in BALF than blood (Table 2), although
the reductions seen were notably less in patients with VAP, as
compared with non-VAP and NVC groups, hence the higher
BALF/blood ratio (Table 2). Other soluble markers IL-1b, IL-8
and sTREM-1 were significantly raised in the VAP compared with
non-VAP groups. IL-6 was similar in VAP and non-VAP groups
but higher than NVC (Figure 2). None of the individual markers
in blood, BALF or BALF/blood ratios had sufficient accuracy in
distinguishing VAP from non-VAP (data not shown).
Classification of individual cases within each study group
using a biomarker panel
To determine whether a biomarker panel might have better
discriminating ability than individual markers, and to separate the
Table 2. Expression of cell-surface and soluble proteins in study participants with VAP, non-VAP and NVC.
VAP Non-VAP NVC
Blood
mTREM-1 5.1 (3.2–8.6) 4.6 (3.1–6.1) 6.5 (4.3–10.9)
nTREM-1 4.7 (2.6–7.3) 3.8 (2.3–6.1) 4.5 (3.1–7.4)
mCD11b 47.2 (30.0–70.0) 43.3 (27.6–52.3) 39.2(21.7–51.8)
nCD11b 44.0 (33.4–91.9) 59.8 (43.4–82.9) 49.0 (38.0–81.0)
mCD62L 9.4 (7.3–15.1) 9.5 (7.4–13.2) 5.4 (3.9–9.4)*
nCD62L 9.6 (6.0–17.0) 8.3 (6.0–10.5) 8.6 (6.8–10.5)
sTREM-1 (mg/ml) 0.18 (0.01–0.03) 0.15 (0.08–0.30) 0.09 (0.06–0.15){,`
IL-1b (mg/ml) N/A N/A N/A
IL-6 (mg/ml) 0.09 (0.03–0.21) 0.08 (0.03–0.17) 0.008 (0.005–0.02)*
IL-8 (mg/ml) N/A N/A N/A
PCT (ng/ml) 1.3 (0.3–5.3) 2.9 (0.6–8.3) N/A*
Corrected BALF
mTREM-1 3.9 (2.5–5.4) 1.6 (1.1–2.3) 1.8 (1.2–2.9)1
nTREM-1 2.0 (1.7–3.3) 1.5 (1.2–2.2)** 1.7 (1.3–3.0)
mCD11b 25.2 (9.0–81.2) 18.6 (13.7–31.2) 21.0 (6.9–47.3)
nCD11b 47.0 (15.1–86.0) 32.9 (20.3–62.5) 24.0 (6.0–73.5)
mCD62L 1.2 (1.0–1.5) 1.1 (1.0–1.3) 1.2 (1.0–1.4)
nCD62L 1.4 (1.0–2.1) 1.1 (1.0–1.4) 1.2 (1.0–1.7)
sTREM-1 (mg/ml) 20.14 (9.45–43.94) 5.19 (2.83–10.96){{ 7.61 (3.05–18.32)
IL-1b (mg/ml) 3.02 (1.47–8.59) 0.79 (0.36–1.51) 0.53 (0.19–2.79)1
IL-6 (mg/ml) 3.80 (1.32–17.71) 2.08 (1.23–5.75) 1.45 (0.52–2.52)``
IL-8 (mg/ml) 48.60 (20.78–101.10) 12.16(5.71–17.3)11 16.33 (3.12–67.15)
PCT (ng/ml) 16.8 (9.7–51.7) 12.5(6.8–27.4) 9.6(4.1–18.2)
Corrected BALF/blood ratio
mTREM-1 0.8(0.5–1.0) 0.4(0.2–0.5) 0.3(0.2–0.4)1
nTREM-1 0.6(0.2–0.8) 0.4(0.3–0.8) 0.4(0.2–1.1)
mCD11b 0.53(0.4–2.3) 0.4(0.2–0.7)11 0.5(0.2–1.3)
nCD11b 0.7(0.5–2.0) 0.5(0.2–0.9) 0.5(0.1–1.4)
mCD62L 0.2(0.1–0.5) 0.1(0.1–0.2) 0.2(0.1–0.3)
nCD62L 0.2(0.1–0.3) 0.2(0.1–0.2) 0.2(0.1–0.2)
sTREM-1 190(70–337) 30(11–85)11 84(26–228)ll
IL-1b N/A N/A N/A
IL-6 77(20–145) 43(41–230) 134(230–355)
IL-8 N/A N/A N/A
PCT 29(3–55) 4(2–23) N/A
The median and interquartile range for each patient group is reported. Statistically significant differences between groups were determined using the Mann-Whitney U
and post hoc Dunn correction as follows: VAP and non-VAP versus NVC (p,0.001)*, VAP versus NVC (p,0.001){ and non-VAP versus NVC (p,0.05)`, VAP versus non-
VAP and NVC (p,0.001)1, VAP versus non-VAP (p,0.01)**, VAP versus non-VAP (p,0.001){{, VAP versus NVC (p,0.01)``, VAP versus non-VAP (p,0.001)11 and NVC.
non-VAP (p,0.01)ll. The lower limits of detection for the sTREM-1, IL-1b, IL-6, IL-8 and PCT assays were 0.01 mg/ml, 0.001 mg/ml, 0.0007 mg/ml, 0.004 mg/ml and 0.05 ng/
ml respectively. N/A indicates below assay detection limit. BALF levels were corrected for dilution occurring with bronchoscopy using urea analysis. BALF/blood ratios
were only calculable if BALF and blood measurements were obtained. VAP = ventilator-associated pneumonia. Non-VAP= ventilated patients with no evidence of
pulmonary infection. NVC= non-ventilated non-infected patients.
doi:10.1371/journal.pone.0109686.t002
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effects of ventilation from infection, Fisher Discriminant Analysis
(FDA) was performed to build a ‘model’ that could best predict to
which group (VAP and non-VAP) a study participant belonged on
the basis of the biological measurements alone. To build the model
we used all the VAP and non-VAP cases in the study and the 22
different markers and their compartmentalized ratios. A seven
marker Bioscore consisting of BALF/blood cell expression ratio for
monocyte mTREM-1 and mCD11b, BALF levels of sTREM-1,
IL-8 and IL-1b, blood levels of CRP and IL-6 was shown to
discriminate between VAP and non-VAP patients.
The 7 marker-bioscore produced 100% correct classification of
the non-VAP patients and 88.9% correct classification of VAP
patients. The NVC group which was treated as an unknown was
defined as non-VAP in 90.7% of the cases using this model. In
order to control for the possibility that the findings of the
biomarker panel might be skewed by results obtained from any
particular patient, we performed a leave one out cross validation
analysis which produced the same level of accuracy with the
original model (100% for non-VAP, 88.9% for VAP).
In order to assess the robustness of the model further, individual
cases were then randomly assigned into a training cohort (60% of
original cases) to obtain new classification function coefficients for
the 7 analytes and the remaining 40% were used as unknowns for
classification. In this cross-validation model the average predictive
accuracies for the patients in the testing cohort were 71.0% for
VAP and 98.5% for non-VAP. The reduction in classification for
VAP was largely driven by the model attributing a number of
NVC as VAP and to the limited power of the testing cohort
analysed.
Discussion
This study demonstrates that a combination of cell surface and
soluble markers of inflammation, in particular TREM-1, sampled
in blood and BALF simultaneously, can accurately discriminate
VAP from ventilated patients without pulmonary sepsis. The use
of a compartmentalization ratio, as a measure of site-specific
immune response, results in a further improvement in diagnostic
classification. These data have implications for the accurate
diagnosis [25], antibiotic usage and management of VAP [26].
The results also address a potential weakness of previous studies
which have measured only soluble mediators, often in one
compartment. These may not fully account for the dynamic
interaction between cell surface receptors and their soluble
counterparts (e.g. mTREM-1 and sTREM-1 respectively), and
site specific flux between the alveolar lung space and blood [27].
The findings suggest that monocytic surface receptor mTREM-
1 and its neutrophilic counterpart nTREM-1 are compartmental-
ized within the lung, with increased expression in VAP. Although
the expression of TREM-1 on pulmonary inflammatory cells has
not to our knowledge previously been assessed in patients with
VAP, the results are consistent with increased mTREM-1 reported
in patients with community acquired pneumonia [28]. Soluble
TREM-1 levels in BALF were significantly elevated and discrim-
inatory in patients with VAP compared to non-VAP, in keeping
with some, [12,14,29,30] but not all studies, [13,31,32]. The
BALF/blood ratio of mTREM-1, mCD11b and sTREM-1 were
significantly higher in patients with VAP compared to those
without VAP suggesting site-specific utility. Pulmonary infection
may be distinguished from abdominal infection by combining
BALF sTREM-1 and blood Procalcitonin measurement, although
with lesser discrimination than our use of combined cell surface/
Figure 1. BALF levels and BALF/blood ratios of monocytic TREM-1. Box (interquartile) and whisker (range) plots showing expression of
TREM-1 by CD14+ monocytes in BALF (Figure 1a) and the BALF/blood ratio of TREM-1 expression by monocytes in blood and BALF (Figure 1b) from
patients with VAP, non-VAP (ventilated non-pulmonary infected control) and NVC (non-ventilated control). BALF levels were corrected for dilution
occurring with bronchoscopy using urea measurement. Statistically significant differences between groups were determined using the Mann-
Whitney U and post hoc Dunn correction as follows: monocyte TREM-1 levels for VAP versus non-VAP and NVC (p,0.001)* and BALF/blood
monocytic TREM-1 ratio VAP versus non-VAP and NVC (p,0.001)*. MFI =mean fluorescence intensity.
doi:10.1371/journal.pone.0109686.g001
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soluble markers [12]. Ramirez et al reported the discriminative
ability of site-sampled sTREM-1 for identifying pulmonary from
abdominal infection in a critically ill cohort [33]. Thus, analysis of
site-specific inflammatory markers may be useful in distinguishing
infective sites, although measurement of cell surface markers over
soluble proteins will not be influenced by dilutional variance from
BALF.
The BALF/blood ratios of neutrophil-based nTREM-1 and
nCD11b were not raised in VAP, unlike their monocytic
counterparts. This difference is consistent with data from patients
in septic shock, in whom blood mTREM-1 but not nTREM-1
levels increased compared with controls [34]. Expression of
TREM-1 on neutrophils initially falls over minutes and then
increases following in vitro LPS stimulation. In contrast TREM-1
levels on monocytes steadily increase over hours. It is possible that
the recruitment timescale for VAP misses early neutrophilic
changes [35]. Indeed, expression of TREM-1 by neutrophils may
have passed its peak before time definitions of VAP allow
measurement. Sampling individuals with suspected VAP at earlier
time points may clarify differential kinetics of TREM-1 expression.
Surface TREM-1 may act as a link in the pathway from
infective organism, to upregulation of the inflammatory cytokines.
That said, it is unlikely to be specific for infection as opposed to
inflammation. Experimentally, mTREM-1 activation in conjunc-
tion with lipopolysaccharride (LPS) increases IL-8 and IL-1b
release, with amplification seen in septic shock, as in our study,
[36,37]. Such changes in IL-8 and IL-1b are in accordance with
Conway-Morris et al, who have demonstrated high area under the
curve (AUC) for them in suspected VAP [13]. Others have found
elevated BALF IL-1b and IL-6 levels in VAP, when using a lung to
Figure 2. Soluble cytokine levels in BALF. Box (interquartile) and whisker (range) plots showing (a) sTREM-1, (b) IL-1b, (c) IL-6 and (d) IL-8 levels
in BALF of patients with VAP, non-VAP (ventilated non-pulmonary infected control) and NVC (non-ventilated control). The BALF levels were corrected
for dilution occurring with bronchoscopy using urea measurement. The concentration of BALF sTREM-1, IL-1b and IL-8 were significantly higher in
VAP than non-VAP (p,0.001)*. BALF IL-1b and IL-6 were higher in the VAP compared with the NVC patient group (p,0.001)**.
doi:10.1371/journal.pone.0109686.g002
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blood ratio like in this study [38]. The BALF/blood ratios of
soluble cytokines were non-discriminatory in this study, perhaps
due to significant compartmentalization by the time of sampling,
producing very low blood levels.
The difference in expression of mTREM-1 in VAP from non-
VAP was more notable in BALF than blood, although the MFI
were lower in BALF (Table 2). This may be due to increased
shedding of up-regulated BALF mTREM-1 within the lung, as
evidenced by the significantly greater increase in soluble sTREM-
1 compared with blood. A potential mechanism is suggested to
involve the balance between bacterial induced metalloproteinase
(MMP) mediated cleavage of TREM-1 from surface of monocytes
and action of specific MMP inhibitors [39]. Moreover, neutrophil
derived MMP production is seen to increase markedly in BALF as
compared to plasma from patients with hospital acquired
pneumonia, whereas the specific tissue inhibitors of MMP (TIMP)
were increased in plasma compared to BALF [40].
The limitations of this study are addressed here. First, no gold
standard for VAP diagnosis exists. We included patients, who
based on the CPIS scoring system, plus semi-quantitative
microbiological testing were highly likely to have the presence or
absence of VAP in order to test putative biomarkers. CPIS has
been criticized by some for its potentially low diagnostic accuracy
based upon clinico-radiological criteria. However, all current
definitions of VAP remain subject to limitations. We acknowledge
that semi-quantitative microbiology is less specific than Quanti-
tative, but as sensitive for identifying pulmonary infection [41].
However, even the use of quantitative microbiology from directed
BALF will potentially miss an important group of VAP patients
(defined by standard clinic-patho-radiological criteria), if not
meeting the predefined cutoff values of colony forming units/ml
(cfu/ml). The arbitrary 48 h requirement for mechanical ventila-
tion in most definitions of VAP provides important standardiza-
tion but will also miss some pulmonary sepsis in ventilated patients
developing prior to that timepoint. In order to mitigate against
these concerns, we redefined the VAP and non VAP patients by
other well established validated international criteria. Thus, the
diagnostic definitions used were highly concordant when the
HELICS criteria for pneumonia were used [15]. Reassuringly,
from a biological perspective, the raised BALF IL-1b and IL-8
levels in VAP from our study concur with a group utilizing
different diagnostic methodology, implying the validity to such
approaches [13]. Therefore, the type of diagnostic criteria,
particularly quantitative microbiology, used were not a major
influence on the bioscore’s discriminability.
Second, this study did not encompass the whole range of
infective aetiologies. For instance, no patients had mycoplasma,
Legionella or proven respiratory viral pneumonias, and few had
bilateral lung infiltrates. The management of viral pneumonias in
particular, would benefit from early diagnostic biomarkers. Third,
the absence of patients with ARDS does not allow us to comment
on how the bioscore might perform in discriminating severe
pulmonary inflammation from pulmonary infection. Fourth, and
from a practical consideration, flow cytometry is a specialized
technique. It requires samples with sufficient numbers of cells,
which mandates adequate directed BALF samples, likely targeted
bronchoscopy and makes serial biomarker analysis challenging.
However, BALF samples are the current standard of care a
microbiological diagnosis of VAP [16]. Fifth, a number of patients
were receiving antibiotics and steroids at the time of sampling,
with potential immunomodulatory activity. Given the prevalence
of these key standard interventions in critically ill patients, we
believe this pragmatic approach enhances the applicability of the
findings. Sixth, the immune response to infecting pathogens in
VAP, as in sepsis, is likely to involve neutrophils, monocytes and
lymphocytes, [42]. As such we have not necessarily looked at all
potentially relevant phagocytic or T cell markers. That said, the
value of biomarker panels that include sTREM-1, PCT and CD64
on neutrophils has recently demonstrated the ability to predict
sepsis in the setting of unselected critical illness, confirming the
need to pursue such discriminatory panels in VAP, as in other
disease states [42,43]. Finally, we acknowledge that these results
require validation in an external cohort of patients with suspected
VAP, to see whether the bioscore 7 panel retains its discriminatory
accuracy. Moreover, such a study is needed to see how the
biomarker components, particularly mTREM-1, sTREM-1, IL1
and IL8, will perform and whether the BALF/blood ratio offers
improved accuracy.
In conclusion, a 7 biomarker panel comprising soluble and cell-
surface inflammatory markers including TREM-1 in combination
with BALF/blood ratio differentiates VAP from non-pulmonary
infection with good diagnostic accuracy. Such an approach, that
incorporates these practically relevant and easily measurable
biomarkers, to confirm or refute suspected VAP, requires
confirmation.
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